ADMP - Adamis begins clinical trial start-up activities for COVID drug; shares rise 5%

loops7/E+ via Getty Images Adamis Pharmaceuticals (ADMP) has begun activities to support the start-up of a clinical trial for Tempol, its COVID-19 drug. These activities include site identification and initiation, data base production, vendor management, and the establishment of an independent data safety monitoring board. The phase 2/3 trial will be conducted by a clinical research organization. Earlier this week, the National Institutes of Health ("NIH") identified Tempol as a potential antiviral COVID-19 drug. Adamis shares are up 4.9% to $1.07 in premarket trading.

For further details see:

Adamis begins clinical trial start-up activities for COVID drug; shares rise 5%